PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
30 août 2023 16h05 HE
|
Allarity Therapeutics, Inc.
- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to...
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
31 juil. 2023 06h00 HE
|
Allarity Therapeutics, Inc.
BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage...
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
24 juil. 2023 06h00 HE
|
Allarity Therapeutics, Inc.
New appointments bring therapeutic development expertise and proven leadership to support continued progress of Allarity’s multiple oncology clinical programs BOSTON (July 24, 2023) — Allarity...
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
06 juil. 2023 06h00 HE
|
Allarity Therapeutics, Inc.
BOSTON, MA (July 6, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
05 juil. 2023 09h45 HE
|
Allarity Therapeutics, Inc.
Boston, MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
28 juin 2023 11h55 HE
|
Allarity Therapeutics, Inc.
- Common Stock Will Begin Trading on a Post-Split Adjusted Basis on June 29, 2023 Press ReleaseBOSTON, MA (June 28, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”),...
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
27 juin 2023 18h16 HE
|
Allarity Therapeutics, Inc.
Press Release BOSTON, MA (June 27, 2023) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
20 juin 2023 16h05 HE
|
Allarity Therapeutics, Inc.
Meeting adjourned to Friday, June 23, 2023 at 1:00 p.m. Eastern Time Press release BOSTON, MA (June 20, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
30 mai 2023 06h00 HE
|
Allarity Therapeutics, Inc.
Phase 2 study evaluating the utility of a DRP® companion diagnostic for cisplatin supports its ability to predict drug response in certain breast cancer patients Boston, MA (May 30, 2023) —...
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
19 avr. 2023 09h18 HE
|
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering BOSTON, MA (April 19, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a...